“Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition of this research facility will strengthen our capabilities in this key area,” said Dr Isao Yanagisawa, senior corporate officer of Astellas Pharma.
Commenting on the sale, Dr Lee Brettman, president and CEO of Dynogen, said that his company would now concentrate on “advancing the development of our five clinical programs and our late-stage preclinical programs.”
Financial details regarding the sale were not disclosed.
Astellas Pharma was formed in April 2005 through the merger of Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical.